gasguide

Succinylcholine

Anectine · Quelicin

Depolarizing neuromuscular blocker

Acetylcholine receptor agonist at the NMJ; sustained depolarization → fasciculations → flaccid paralysis. Hydrolyzed by plasma cholinesterase.

Indications

  • RSI
  • Laryngospasm rescue
  • ECT (modify motor seizure)
  • Brief paralysis

Dosing

ContextAdultPediatric
RSI1–1.5 mg/kg IV2 mg/kg IV; 4 mg/kg IM
Laryngospasm0.1–0.5 mg/kg IV; 2–4 mg/kg IM if no IV

Pharmacokinetics

Onset 30–60 sec. Duration 5–10 min. Plasma pseudocholinesterase metabolism.

Side effects

  • !Hyperkalemia (↑0.5 mEq/L normally; severe in burns > 24 h, denervation, prolonged immobility, MS, ALS, Guillain-Barré)
  • !Bradycardia/arrhythmia (especially repeat dose, peds — pretreat with atropine)
  • !Masseter rigidity (may herald MH)
  • !Postoperative myalgia
  • !↑ICP, ↑IOP, ↑intragastric pressure
  • !Pseudocholinesterase deficiency → prolonged block (4–8 h vs. 5 min)
  • !Anaphylaxis

Contraindications

  • ×Personal/family hx malignant hyperthermia
  • ×Hyperkalemia
  • ×Burns > 24 h, denervation injury, prolonged immobility (upregulated extrajunctional ACh receptors)
  • ×Open globe injury (relative)

Reversal / antidote

Wait it out (5–10 min); no pharmacologic reversal. Prolonged block from pseudocholinesterase deficiency: continue ventilation until block resolves (FFP not standard).

Clinical pearls

  • Always have atropine drawn for peds doses > 0.5 mg/kg.
  • Phase II block can mimic non-depolarizing block at high cumulative doses.
  • Defasciculation pretreatment of NDMR ↓ myalgia, ↑ sux dose required by 70%.
Education only — confirm against current package inserts and institutional protocols. Doses assume normal organ function unless otherwise noted.